date,title,source
Oct-18-18,"Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-23-18,Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today,Motley Fool
Oct-23-18,3 Healthcare Stocks Trending Higher On News,ACCESSWIRE
Oct-23-18,CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited,PR Newswire
Oct-24-18,Todays Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences,ACCESSWIRE
Nov-14-18,CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results,PR Newswire
Nov-16-18,"CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China",PR Newswire
Nov-28-18,"Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Nov-30-18,"Chinese biotech stocks hit by a double whammy, which means its time to buy",MarketWatch
Dec-03-18,The 4 Healthcare Stocks To Watch On Monday,ACCESSWIRE
Dec-26-18,"Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?",Simply Wall St.
Dec-28-18,These 4 Healthcare Stocks Are Heating Up,ACCESSWIRE
Feb-06-19,CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference,PR Newswire
Feb-20-19,"Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett  Future Expectations, Projections Moving into 2019",GlobeNewswire
Feb-26-19,"When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?",Simply Wall St.
Mar-29-19,CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results,PR Newswire
Apr-02-19,"CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer",PR Newswire
Apr-17-19,CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics,PR Newswire
